Pharmaceutical innovation in the 21st century: New drug approvals in the first decade, 2000-2009

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 2, 2011, Pages 183-188

  Kaitin, K I ^a   Dimasi, J A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; GASTROINTESTINAL AGENT; HORMONE; IMMUNOLOGIC AGENT; ORPHAN DRUG;

ARTICLE; DECISION MAKING; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG LEGISLATION; DRUG RESEARCH; ECONOMICS; PRESCRIPTION DRUG USE FEE ACT; PRIORITY JOURNAL;

DRUG APPROVAL; DRUG DISCOVERY; DRUG INDUSTRY; LEGISLATION, DRUG; ORPHAN DRUG PRODUCTION; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78951480503     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.286     Document Type: Article

References (20)

1. Public Health Security and Bioterrorism Preparedness and Response act of 2002, Pub. L. No. 107-188, 12 June 2002.
2. National Center for Research Resources fact Sheet. Clinical and Translational Science awards (Summer 2010). http://ncrr.nih.gov/publications/ pdf/ctsa-factsheet.pdf.
3. Woolf, S.H. The meaning of translational research and why it matters. JAMA 299, 211-213 (2008).
4. Milne, C.P. & Kaitin, K.I. Translational medicine: an engine of change for bringing new technology to community health. Sci. Transl. Med. 1, 5cm5 (2009).
5. US food and Drug administration. Innovation or Stagnation: Challenges and Opportunity on the Critical Path to New Medical Products http://www.fda.gov/ ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/ucm077262.htm (March 2004).
6. Council of the European Union. Council Regulation Setting Up the Joint Undertaking for the Implementation of the Joint Technology Initiative on Innovative Medicines http://register.consilium.europa.eu/pdf/en/07/st15/st15977. en07.pdf (2007).
7. DiMasi, J.A. & Grabowski, H.G. The cost of biopharmaceutical R&D: is biotech different? Manag. Decis. Econ. 28, 469-479 (2007).
8. DiMasi, J.A., Feldman, L., Seckler, A. & Wilson, A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272-277 (2010).
9. Munos, B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959-968 (2009).
10. Deloitte Consulting LLP. alternative Business Models for Life Sciences R&D. September 2009.
11. Kaitin, K.I. Deconstructing the drug development process: the new face of innovation. Clin. Pharmacol. Ther. 87, 356-361 (2010).
12. Melese, T., Lin, S.M., Chang, J.L. & Cohen, N.H. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat. Med. 15, 502-507 (2009).
13. Getz, K. fIPNet: Pharma's new, Sexy, But not yet ready for prime-time model http://www.nxtbook.com/nxtbooks/advanstar/insideoutsourcing-200911/#/1 (2009).
14. Luce, C.B. & Hassenplug, M.B. Mimicking biotech: pharma's move to innovative R&D models. The RPM Report. f-D-C Reports and Windhover Information, April 2009.
15. David, E., Mehta, A., Norris, T., Singh, N. & Tramontin, T. New frontiers in pharma R&D investment. McKinsey Quarterly. McKinsey. february 2010.
16. Prescription Drug User fee act of 1992, Pub. L. No. 102-571 (1992), 21 USC 379; 106 Stat. 4491.
17. Slater, E.E. & Kaitin, K.I. Explaining the drug drought. Pharmaceut. Executive 30, 22-24 (2010).
18. Davies, J. & Davies, D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 74, 417-433 (2010).
19. Akil, H. et al. Medicine. The future of psychiatric research: genomes and neural circuits. Science 327, 1580-1581 (2010).
20. Kaitin, K.I. (ed.). Rising Protocol Complexity, Execution Burden Varies Widely by Phase and TA, Vol. 12, No. 3 (Tufts Center for the Study of Drug Development Impact Report, Boston, May/June 2010).